Allergan plc Expected to Post Q1 2019 Earnings of $3.55 Per Share (AGN)

Allergan plc (NYSE:AGN) – Equities researchers at Jefferies Financial Group issued their Q1 2019 earnings per share estimates for shares of Allergan in a research report issued on Monday, April 15th, Zacks Investment Research reports. Jefferies Financial Group analyst D. Steinberg forecasts that the company will post earnings of $3.55 per share for the quarter. Jefferies Financial Group currently has a “Hold” rating and a $144.95 price target on the stock. Jefferies Financial Group also issued estimates for Allergan’s Q2 2019 earnings at $4.20 EPS, Q3 2019 earnings at $4.08 EPS, Q4 2019 earnings at $4.56 EPS, FY2019 earnings at $16.38 EPS, FY2020 earnings at $17.16 EPS, FY2021 earnings at $17.80 EPS, FY2022 earnings at $18.12 EPS and FY2023 earnings at $18.82 EPS.

Allergan (NYSE:AGN) last announced its quarterly earnings data on Tuesday, May 7th. The company reported $3.79 EPS for the quarter, beating the Zacks’ consensus estimate of $3.55 by $0.24. Allergan had a negative net margin of 32.28% and a positive return on equity of 8.18%. The business had revenue of $3.60 billion during the quarter, compared to analyst estimates of $3.55 billion. During the same quarter in the prior year, the business earned $3.74 earnings per share. The firm’s revenue for the quarter was down 2.0% on a year-over-year basis.

Several other analysts have also weighed in on AGN. SunTrust Banks assumed coverage on shares of Allergan in a report on Tuesday, March 19th. They set a “buy” rating and a $178.00 price objective for the company. ValuEngine raised shares of Allergan from a “strong sell” rating to a “sell” rating in a report on Tuesday, January 15th. Credit Suisse Group set a $155.00 price objective on shares of Allergan and gave the stock a “hold” rating in a report on Monday, March 25th. Royal Bank of Canada set a $165.00 price objective on shares of Allergan and gave the stock a “hold” rating in a report on Monday, March 25th. Finally, UBS Group dropped their price objective on shares of Allergan from $174.00 to $173.00 and set a “buy” rating for the company in a report on Wednesday, April 3rd. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $184.52.

NYSE:AGN traded down $0.10 during mid-day trading on Tuesday, hitting $140.16. The company’s stock had a trading volume of 2,572,311 shares, compared to its average volume of 2,549,160. Allergan has a fifty-two week low of $125.84 and a fifty-two week high of $197.00. The company has a quick ratio of 0.98, a current ratio of 1.13 and a debt-to-equity ratio of 0.35. The firm has a market capitalization of $48.50 billion, a PE ratio of 8.40, a price-to-earnings-growth ratio of 1.34 and a beta of 1.32.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Tuesday, May 14th will be issued a dividend of $0.74 per share. The ex-dividend date of this dividend is Monday, May 13th. This represents a $2.96 dividend on an annualized basis and a dividend yield of 2.11%. Allergan’s payout ratio is 17.74%.

Allergan declared that its board has authorized a stock repurchase program on Tuesday, January 29th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the company to purchase up to 4.1% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

In related news, Chairman Brent L. Saunders acquired 1,760 shares of the company’s stock in a transaction that occurred on Thursday, March 7th. The shares were acquired at an average cost of $143.67 per share, for a total transaction of $252,859.20. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.08% of the company’s stock.

A number of hedge funds have recently modified their holdings of AGN. Oregon Public Employees Retirement Fund increased its stake in Allergan by 14,208.8% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 20,762,744 shares of the company’s stock valued at $155,000 after buying an additional 20,617,639 shares during the last quarter. Longview Partners Guernsey LTD increased its stake in Allergan by 288.6% in the 4th quarter. Longview Partners Guernsey LTD now owns 6,026,108 shares of the company’s stock valued at $805,450,000 after buying an additional 4,475,447 shares during the last quarter. Norges Bank acquired a new stake in Allergan in the 4th quarter valued at $484,853,000. Janus Henderson Group PLC increased its stake in Allergan by 27.6% in the 1st quarter. Janus Henderson Group PLC now owns 5,855,576 shares of the company’s stock valued at $857,312,000 after buying an additional 1,265,742 shares during the last quarter. Finally, Ellis Investment Partners LLC increased its stake in Allergan by 14,302.8% in the 1st quarter. Ellis Investment Partners LLC now owns 852,214 shares of the company’s stock valued at $852,000 after buying an additional 846,297 shares during the last quarter. Hedge funds and other institutional investors own 80.95% of the company’s stock.

Allergan Company Profile

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.

Featured Story: How do buyers and sellers choose a strike price?

Get a free copy of the Zacks research report on Allergan (AGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.